Guanfacine hydrochloride (TAK-503)
SPD503-401
Approved small_molecule completed
Quick answer
Guanfacine hydrochloride (TAK-503) for Attention Deficit Hyperactivity Disorder is a Approved program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Attention Deficit Hyperactivity Disorder
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed